---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-034076"
form_type: "8-K"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2023-12-11T23:59:59+00:00"
generated_at: "2026-06-07T14:40:12.924953+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cassava Sciences expands board to 9 with three new directors

## Summary
- Appointed Dr. Claude Nicaise, Pierre Gravier, and Robert Anderson, Jr. effective Dec 6, 2023.
- Board expanded from 6 to 9 members; Anderson (Class I), Nicaise and Gravier (Class II).
- Nicaise led regulatory/clinical roles resulting in 14 drug approvals; Gravier is CFO of PTC Therapeutics.
- Anderson is former FBI Executive Assistant Director and cybersecurity expert.
- No committees assigned; none have material interests in reportable transactions.

## SEC filing metadata
- accession: 0001437749-23-034076
- form_type: 8-K
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2023-12-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000143774923034076/0001437749-23-034076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000143774923034076/sava20231208c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-034076
- JSON: https://secwatch.observer/filing/0001437749-23-034076.json
- Plain text: https://secwatch.observer/filing/0001437749-23-034076.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.